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Bone remodeling is regulated by secreted factors in the bone microenvironment. However, data
regarding osteoclast-derived factors that inﬂuence osteoblast differentiation are lacking. Here, we
show that HtrA1 is produced as a secreted protein during osteoclastogenesis, and negatively
regulates osteoblast differentiation. Exogenous addition of recombinant HtrA1 attenuates osteoblast
differentiation and BMP2-induced Smad1/5/8, ERK1/2 and p38 phosphorylation in pre-osteoblasts.
Our studies imply a uniquemode of crosstalk inwhichHtrA1 is produced by both osteoclasts and oste-
oblasts and negatively regulates osteoblast differentiation, suggesting that HtrA1maymediate the ﬁne
tuning of paracrine and autocrine regulations during bone remodeling processes.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bone, a specialized connective tissue, is coordinately regulated
by two different types of cells, namely bone-forming osteoblasts
and bone-resorbing osteoclasts [1]. Osteoblasts are differentiated
frommesenchymal stem cells and are responsible for the synthesis
and mineralization of bone. Osteoclasts are derived from haemato-
poietic stem cells, and are the principal cells for bone resorption.
Through the coupling of bone resorption and formation by osteo-
clasts and osteoblasts, bone tissue undergoes constant remodeling
[1]. Deciphering the molecular mechanisms regulating the coordi-
nated action of osteoclasts and osteoblasts is important for our
understanding of bone remodeling [1]. It is of particular interest
to identify osteoclast-derived factors that regulate osteoblasts by
paracrine mechanism in the bone microenvironment.
Secreted factors or ligand and receptor signaling networks are
believed to play a critical role in the communication betweenosteoclasts and osteoblasts [1]. For example, osteoblasts control
the formation and activity of osteoclasts via the receptor activator
of NF-jB ligand (RANKL) system, a membrane-bound protein that
is expressed by osteoblasts and binds to its receptor RANK on
osteoclast precursors [2]. Semaphorin 4D is expressed by
osteoclasts and inhibits bone formation by binding to its receptor
Plexin-B1 on osteoblasts and regulating RhoA signaling [3]. These
data point to a complex paracrine and autocrine mechanisms of
intercellular communications in the bone microenvironment. In
order to fully understand the crosstalk between osteoclasts and
osteoblasts, novel secreted or membrane bound molecules pro-
duced by osteoclasts that is capable of inﬂuencing osteoblast
differentiation remain to be vigorously uncovered.
HtrA (high temperature requirement protease A) proteins
belong to a family of serine proteases, and four types of HtrA have
been identiﬁed, HtrA1, HtrA2, HtrA3, and HtrA4, which share a
common trimeric pyramidal architecture where each monomer
comprises a serine protease domain and one or two PDZ domains
[4]. The HtrA family is involved in a variety of biological functions
such as mitochondrial homeostasis, and apoptosis and in the
pathogenesis of several diseases including, Alzheimer’s disease,
age-related macular degeneration, osteoarthritis, neurodegenerative
144 X. Wu et al. / FEBS Letters 588 (2014) 143–150disorders, and cancer [5,6]. HtrA1 expression has been found to be
temporally increased in differentiating 2T3 osteoblasts prior to the
appearance of mineralization, and then down regulated in fully
mineralized culture [7]. When overexpressed endogenously, HtrA1
negatively regulated osteoblast mineralization [7]. However, it is
hitherto unknown in regards to the expression of HtrA1 during
RANKL-induced osteoclast formation and its role as an exogenous
factor in osteoclast and osteoblast differentiation. Moreover, the
effect of HtrA1 on BMP signaling of small mother against decapen-
taplegic (Smad) and mitogen-activated protein kinases (MAPK)
such as ERK1/2 and p38 remains to be elucidated.
In this study, in an attempt to hunting for osteoclast-derived
factors that mediate osteoblast differentiation, we have strategi-
cally screened for novel molecules that are differentially regulated
during osteoclast differentiation using microarray analysis. We dis-
covered that HtrA1 gene expression is highly induced during
RANKL-induced osteoclastogenesis, and the most prominent
RANKL-responsive isoform within the HtrA family members. We
observed that HtrA1 is secreted by osteoclasts and as an exogenous
factor negatively regulates osteoblastic differentiation but does not
affect osteoclast differentiation. Furthermore, we showed that
HtrA1 inhibits BMP2-induced Smad1/5/8, ERK1/2 and p38
phosphorylation and osteoblast marker gene expression. Taken
together, this study and other work show that HtrA1 is produced
by both osteoclasts and osteoblasts and negatively regulates osteo-
blast differentiation and BMP-induced Smad and MAPK signaling.
2. Materials and methods
2.1. Media and reagents
Alpha Modiﬁed Eagles Medium (a-MEM) and fetal bovine
serum (FBS) was purchased from Life Technologies (Life Technolo-
gies, Australia). Recombinant Human HtrA1/PRSS11 and bone
morphogenetic protein 2 (BMP2) were purchased from R&D
Systems (R&D, USA). p-Nitrophenyl phosphate (pNPP) and 1,25-
dihydroxyvitamin D3 (Vit D3) was purchased from Sigma (Sigma,
Australia). Recombinant RANKL protein was expressed and puriﬁed
as previously described [8].
2.2. Cells and cell culture
KusaO cell is a mouse bone marrow stromal cell line established
for studying osteoblast differentiation [9]. KusaO cells were main-
tained in a-MEM as previously described [10]. Primary mouse
bone marrow macrophages (BMM) were isolated from C57BL/6J
mice. Bone marrow was collected from femora and tibia of 8- to
12-week-old mice by ﬂushing the bone with complete a-MEM fol-
lowed by ﬁltration through a 100 lmmesh. BMMwere cultured in
complete a-MEM. Primary calvarial osteoblasts were isolated from
mice according to our previously described protocol [10].
2.3. In vitro osteoclastogenesis assay
BMMwere seeded onto a 96-well plate (6  103 cells/well) with
complete a-MEM medium containing M-CSF (25 ng/ml) and in the
presence or absence of RANKL (50 ng/ml) for 5 days. Cells were
then ﬁxed and stained using a Tartrate-resistant acid phosphate
(TRACP) kit (Sigma, Australia). TRACP positive cells with more than
three nuclei were counted as osteoclasts.
2.4. RNA isolation, cDNA array, and semiquantitative reverse
transcription (RT)-PCR
Total RNA was isolated from the cultures using RNA extraction
kit (Qiagen, Victoria, Australia). The RNA concentration wasdetermined by measuring the absorbance at 260 nm with a
Nano-drop 2000 (Thermo Scientiﬁc), and quality assessed using
Agilent Bioanalyzer. Gene expression of HtrA family members
during in vitro osteoclast differentiation was detected by cDNA
microarray. Microarray protocols were performed with two inde-
pendent sets of paired samples of BMM and osteoclasts by mouse
expressionWG6 beadchip according to the manufacturer’s instruc-
tions (Illumina Inc.). For RT-PCR, single stranded cDNA was
prepared from 2 lg of total RNA using reverse transcriptase with
oligo-dT primer. All PCR was performed using cycling parameters
94 C, 40 s; 55 C, 40 s; 72 C, 40 s for 30 cycles with primers listed
in Supplementary Table 1.
2.5. Real-time PCR (qPCR)
qPCR was used to deﬁne gene expression of HtrA1. qPCR was
performed using SYBR green (Qiagen, Australia) and iCycler
(BioRad) according to manufacturer’s instructions. PCR ampliﬁca-
tion was performed using a proﬁle with 94 C for 1 min (denatur-
ation), 60 C for 30 s (annealing), 72 C for 45 s (elongation) for a
total of 38 cycles, followed at the end by 72 C for 5 min (extension).
Negative controls without RT were carried out in parallel for every
PCR reaction to exclude ampliﬁcation of contaminating DNA. 18S
ribosomal RNA (18S) was chosen as an internal control to standard-
ize the variability. After ampliﬁcation, a dissociation analysis was
performed to evaluate the presence or absence of non-speciﬁc
ampliﬁcations in each PCR reaction.
2.6. In vitro osteoblastogenesis assay
KusaO cells were cultured in osteogenic differentiation medium
as previously described [10]. Cells were then ﬁxed and stained
using the leukocyte alkaline phosphatase kit (Sigma, Australia)
according to the manufacturer’s instructions. To quantify alkaline
phosphatase (ALP) activity, in cells unﬁxed monolayers were
washed with PBS, and lysed with 1% Triton-X 100 in milliQ water.
ALP activity was assessed using pNPP (70 mM) as substrate in AMP
reagent buffer (420 mM 2-amino-2-methyl-1-propanol, 1 mM
magnesium chloride, 1 mM zinc chloride pH 10.3), and measuring
the change in absorbance at 405 nm. ALP levels were normalised to
total protein concentrations as measured by Bradford assay.
2.7. Cell proliferation assay
Cell proliferation was examined using the CellTiter 96 Aque-
ous Non-Radioactive Cell Proliferation Assay (Sigma, Australia)
according to the manufacturer’s instructions.
2.8. Western blot analysis
Western blot was performed according to our previously
described protocol [10]. The primary antibodies used in the exper-
iment included anti-HtrA1 (1:250, Santa Cruz Biotechnology),
anti-phospho-Smad1/5/8 (1:1000, Cell Signaling), Smad1 (1:1000,
Cell Signaling), anti-phospho-ERK1/2 (1:1000, Santa Cruz Biotech-
nology), anti ERK1/2 (1:5000, Promega), anti-p38 MAPK (1:1000
dilution, Cell Signaling), anti-phospho-p38 MRPK (1:1000 dilution,
Cell Signaling), anti-b-actin (JLA20) (DSHB University of Iowa). An
anti-V-ATPase d2 antibody was generated by the Polyclonal Anti-
body Production Facility in the School of Molecular and Biomedical
Sciences, University of Adelaide [11]. Horseradish peroxidase
(HRP)-conjugated anti-mouse and anti-rabbit antibodies (1:5000
dilution, Santa Cruz Biotechnology) were used as secondary anti-
bodies. The membranes were then visualized using the ECL system
(Amersham, Australia). b-Actin was used to conﬁrm equal protein
loading.
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All measurements were collected in triplicate. Unless otherwise
stated, all data are presented as the Mean ± S.D. One-way ANOVA
or Student’s t-test was used to detect differences between the var-
ious treatment groups. P values of less than 0.05 were considered
to be statistically signiﬁcant.
3. Results
3.1. HtrA family genes are differentially expressed during RANKL-
induced osteoclastogenesis
To identify osteoclast-derived factors that are involved in the
regulation of osteoblast differentiation, microarray analysis was
performed on cDNA isolated from osteoclasts and BMM. HtrA
family genes are found to be differentially expressed during
RANKL-induced osteoclast differentiation, as shown by the heat-
map analysis (Fig. 1A). Among all four members of the HtrA family,
HtrA1 was most highly up-regulated based on microarray analysis
(Fig. 1B). Multiple sequence alignment and guide tree analysis of
the amino acid sequences of mouse HtrA family proteins showsA
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Fig. 1. Microarray analysis of HtrA family gene expression during osteoclast differentiati
BMM cells (pre-OC) and mature osteoclasts (OC) were harvested for microarray analys
differentiation, with osteoclast speciﬁc genes. Up-regulation and down-regulation are sh
family members in microarray analysis. (C) Multiple alignment of full length protein sequ
using Uniprot program.that HtrA1 is most closely related to HtrA4, followed by HtrA3
and HtrA2 (Fig. 1C and D). Sequence analysis further indicates that
HtrA1, HtrA3, and HtrA4 exhibit characteristics of a secreted
protein; including a signal peptide sequence at the N-terminus
and lack a transmembrane domain. Given that microarray and bio-
informatics analyses hint that HtrA1 is most highly induced by
RANKL and bears characteristics of a secreted protein, it prompted
us to investigate the role of HtrA1 in osteoblast and osteoclast dif-
ferentiation as an exogenous factor.
3.2. HtrA1 is highly induced by RANKL during osteoclast differentiation
The induction of HtrA1 gene by RANKL was further conﬁrmed
by qPCR analysis. The results showed a 14.68-fold increase in
HtrA1 mRNA levels in osteoclasts at day 5 after RANKL treatment,
as compared to day 0 (Fig. 2A). The upregulation of HtrA1 is in line
with other established osteoclast marker genes, including TRACP
and dendritic cell-speciﬁc transmembrane protein (DC-Stamp)
(Fig. 2B and C). By comparison, we also examined the gene expres-
sion of HtrA1 during calvarial osteoblast differentiation. qPCR anal-
ysis demonstrated that HtrA1 was up-regulated during osteoblast
differentiation in line with other established osteoblast markersHtrA2
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Fig. 2. HtrA1 is up-regulated during osteoclast and osteoblast differentiation. (A–C) HtrA1 is signiﬁcantly up-regulated during osteoclast differentiation. Gene expression was
examined by qPCR analysis using primers speciﬁc for (A) HtrA1 and osteoclast speciﬁc genes (B) TRACP and (C) DC-Stamp. (D–F) HtrA1 is signiﬁcantly up-regulated during
primary calvarial osteoblast differentiation. Gene expression was examined by qPCR analysis using primers speciﬁc for (D) HtrA1, and osteoblast speciﬁc genes (E) OCN and
(F) OPN. The gene expressions are normalized to 18S and compared to the expression at day 0. (G and H) The protein levels of HtrA1 were up-regulated during (G) osteoclast
differentiation and (H) osteoblast differentiation. ⁄P < 0.05.
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4.52-fold increase in HtrA1 mRNA levels in osteoblasts at day 21
as compared to day 0 (Fig. 2D–F).
In addition, we examined the protein expression of HtrA1 in
osteoclasts. Both supernatant and cell lysates were collected and
were subjected to Western blot analysis. As shown in Fig. 2G,
HtrA1 was expressed in and secreted by osteoclasts. Osteoclast
marker, V-ATPase d2 was used as a control [11]. Our results
conclude that HtrA1 is a secreted protein induced by RANKL during
osteoclastogenesis. Thus, these data document the ﬁrst evidence of
HtrA1 expression by osteoclasts. HtrA1 protein was also upregu-
lated throughout osteoblast differentiation (Fig. 2H). EGFL6, a se-
creted factor that is known to be upregulated during osteoblast
differentiation [10] was used as a control. In addition, analysis oftissue distribution revealed that the level of HtrA1 mRNA
expression was highly expressed in the brain, heart and ovary
(Supplementary Fig. S1).
3.3. HtrA1 inhibits osteoblast differentiation but does not affect cell
proliferation
Next, we examined effect of HtrA1 as an exogenous factor on
osteoblast differentiation and proliferation using KusaO cells.
KusaO cell, a bone marrow stromal cell line is a subclone of Kusa
cells which have been well established and widely used to study
osteoblast differentiation and physiology [9,12]. We found that
HtrA1 signiﬁcantly inhibited BMP2-induced ALP activity by ALP
staining and activity assay (Fig. 3A and B). In addition, we found
p-ERK1/2
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p-p38
p38
0 1 2 5 1 2 5hrs
β-actin
A
B
Smad1
p-Smad1/5/8
β-actin
mins 0 10 20 30 10 20 30
BMP2 BMP2 + HtrA1
BMP2 BMP2 + HtrA1
Fig. 4. HtrA1 inhibits BMP2-induced Smad1/5/8, ERK1/2 and p38 phosphorylation.
The cellular phosphorylation levels of Smad1/5/8, ERK1/2 and p38 were determined
byWestern blot analysis after KusaO cells were stimulated with BMP2 (50 ng/ml) in
the presence or absence of HtrA1 (100 ng/ml) for the indicated time points. b-Actin
was used as a loading control.
X. Wu et al. / FEBS Letters 588 (2014) 143–150 147that HtrA1 also inhibited the mineralization of KusaO cells in a
dose dependent manner (data not shown), which is in agreement
with previous observations that forced expression of endogenous
HtrA1 inhibits osteoblast mineralization [7]. Next, we sought to
investigate the effects of HtrA1 on osteoblast marker gene expres-
sion. KusaO cells were cultured in osteogenic differentiation
mediumwith BMP2, in the presence or absence of HtrA1 for 7 days.
RNA was then harvested, followed by qPCR analysis. HtrA1 signif-
icantly inhibits BMP2-induced osteoblast marker gene expression
including ALP, Runx2, OCN and OPN (Fig. 3C–F). Moreover, HtrA1
has no signiﬁcant inductive or inhibitory effect on the proliferation
of KusaO cells (data not shown).
3.4. HtrA1 inhibits BMP2-induced phosphorylation of Smad1/5/8, ERK
and p38 in osteoblastic like cells
It has been demonstrated that HtrA1 acts as an antagonist to
transforming growth factor-b (TGF-b) family members including
BMP2 [6,13]. Interestingly, it was shown that HtrA1 inhibits
BMP2-induced signaling in C2C12 myoblast cells [13]. To
investigate the potential mechanism by which HtrA1 inhibits
BMP2-induced osteoblast differentiation, we examined the effect
of HtrA1 on BMP2 signaling pathways, Smad and MAPK in KusaO.
As shown in Fig. 4A, HtrA1 signiﬁcantly inhibited BMP2-induced
Smad1/5/8 phosphorylation. Next, we examined the effect of HtrA1
on MAPK signaling. Previous study suggested that BMP2 induced
ERK1/2 and p38 phosphorylation peaking at 2–5 h [14]. Here, we
showed that both BMP2-induced ERK1/2 and p38 phosphorylationA Control BMP2
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Fig. 3. HtrA1 inhibits osteoblastic-like cell differentiation and osteoblast marker gene expressions. (A) KusaO cells were cultured in osteogenic medium with HtrA1 (100 ng/
ml) in the presence or absence of BMP2 (50 ng/ml) for 4 days, followed by ALP staining. (B) Quantiﬁcation of ALP activity shown as a percentage relative to untreated cell
lysates. (C–F) KusaO cells were cultured in osteogenic differentiation medium with BMP2 (50 ng/ml) in the presence or absence of HtrA1 (100 ng/ml) for 7 days. RNA were
harvested, followed by qPCR analysis. HtrA1 signiﬁcantly inhibit BMP2-induced osteoblast marker gene expression including (C) ALP, (D) Runx2, (E) OCN and (F) OPN.
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control.
3.5. HtrA1 does not affect RANKL-induced osteoclastogenesis
Next, we examined the effect of HtrA1 on RANKL-induced
osteoclastogenesis. BMMwere incubated with different concentra-
tions of HtrA1 in the presence or absence of RANKL, and the
number of osteoclast counted. BMM cultured in the presence of
M-CSF and RANKL formed typical TRACP-positive osteoclasts.
Addition of HtrA1 protein into BMM cultures showed no signiﬁcant
effect on the formation of osteoclast as measured by the TRACP po-
sitive multinucleated cells (Fig. 5A and B). These results suggest
that HtrA1 did not impact osteoclastogenesis in BMM cultures.
3.6. HtrA1 has little effects on the ratio of RANKL/OPG gene expression
in osteoblast lineage
To investigate whether HtrA1 has an indirect effect on
osteoclastogenesis, we examined the regulation of RANKL/OPG
gene expression in osteoblasts. KusaO cells were treated with
100 ng/ml HtrA1 for 24 h. 1,25-dihydroxyvitamin D3 (Vit D3) at
the concentration of 10 nM was used a as a positive control for
the regulation of RANKL/OPG gene expression. Semiquantitative
RT-PCR and qPCR results show that HtrA1 does not signiﬁcantly al-
ter the gene expression of RANK/OPG. As a positive control, Vit D3
induced both RANKL and OPG gene expression in KusaO cells
(Fig. 5C–E).- RANKL RANKL
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Fig. 5. HtrA1 does not have direct or indirect effects on osteoclast formation. (A) BMM c
absence of HtrA1. Cells were then ﬁxed and stained for TRACP activity. (B) Quantitation
HtrA1 (100 ng/ml) for 48 h. Vit D3 (10nM) was used as a positive control. Semiquantitati
(D) and RANKL (E). Gene expression were normalized to 18S expression and presented4. Discussion
The crosstalk between osteoblasts and osteoclasts is an essen-
tial requirement for the balancing act of bone remodeling, and
the disruption of coordinated activities between osteoclasts and
osteoblasts contributes to bone pathogenesis and diseases [1]. Dis-
covering novel osteoclast-derived factors that mediate osteoblasts
has become increasingly important to understand the molecular
mechanism of the crosstalk between osteoclasts and osteoblasts.
In this study, we showed that HtrA1 is highly up-regulated in
RANKL-induced osteoclastogenesis and, as a secreted factor, has a
negative regulation on osteoblast differentiation, but has little im-
pact on osteoclast differentiation.
A previous study has shown that HtrA1 is temporally up-regu-
lated during osteoblast mineralization but inhibits mineralization
by an autocrine fashion, with its expression peaking at day 17,
and gradually subdued in 2T3 cell culture [7]. By comparison, using
primary mouse osteoblast culture, we have found that HtrA1 is
constantly unregulated during osteoblast differentiation from day
0 to 21. This discrepancy might be due to two different cell types
being used. Consistent to our observations, a more recent study
has also shown that HtrA1 is up-regulated by BMP2 and BMP7
during osteoblastic differentiation of C2C12 cells [15]. Neverthe-
less, our studies extended previous ﬁndings [7] to show that osteo-
clast-derived HtrA1 has an inhibitory effect on osteoblast
differentiation and gene expression, in addition to its effect on
osteoblast mineralization process. In addition, since HtrA1 isl)
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osteoblast differentiation, it implies for a paracrine mode of action
in addition to its autocrine effect as previous reported [7]. Based on
these new ﬁndings, a working model of HtrA1 is proposed (Fig. 6A),
which highlights a unique mode of HtrA1 action that is different
from other molecules that are recently implicated in the crosstalk
of osteoclasts and osteoblasts.
Surprisingly, in a disagreement with our ﬁndings, a recent study
has proposed that HtrA1 could positively regulate osteoblast dif-
ferentiation of human mesenchymal stem cells [16]. One of the
reasons to these different ﬁndings could be due to the various
doses and source of HtrA1 being used. It is important to note that
a very high dose of HtrA1 (5 lg/ml) was employed in Tiaden’s
study [16], which are 25–50 times more than what was used in this
study (100–200 ng/ml). However, it is interesting to point out that
TGF-b family members such as TGF-b1 and BMP4 have bidirec-
tional dose-dependent effects on cellular activities [17–19]. Thus,
HtrA1, in a dose-dependent manner might result in a biphasic ef-
fect on osteoblast differentiation. If this is the case for a biphasic
effect, then it should raise an intriguing possibility that when
HtrA1 is induced far in excess in bone microenvironment during
RANKL-mediated osteoclastogenesis, it might confer to a positive
effect on osteoblast differentiation, thus providing a ﬁne tuning
of the balancing act by osteoclast and osteoblast-mediated bone
remodeling processes.
Moreover, we have found that HtrA1 can temper the BMP2-in-
duced activation of Smad1/5/8, ERK1/2 and p38 in osteoblastic like
cells and the gene expression of ALP, Runx2, OCN and OPN. Given
that HtrA1 is able to bind to TGF beta family proteins to prevent
receptor activation, and inhibit signaling by BMP2, BMP4, and
TGF-beta1 in C2C12 cells [13], it is possible that HtrA1 inhibits
the BMP2-mediated phosphorylation of Smad1/5/8, ERK1/2 and
p38 and osteoblast differentiation via its direct binding and inacti-
vation of BMP2 (Fig. 6B).
Recently, the expression of HtrA1 was also found to be
increased in the articular cartilage degeneration, such as type IX
collagen-deﬁcient and type XI collagen-haploinsufﬁcient [20,21].
Interestingly, a genetic variation at the HtrA1 gene promoter locus
has been identiﬁed to be associated with spinal disc degeneration
[22]. Moreover, it was reported that HtrA1 regulated angiogenesis
through TGF-b family member [23]. Vascular supply is important
in bone homeostasis, including subchondral region [24]. Thus itFig. 6. Proposed model of HtrA1 function in the communication between osteoclasts a
osteoclasts and osteoblasts and negatively regulates osteoblast differentiation. Conversel
inhibited BMP2-induced Smad and MAPK signaling pathways in osteoblast.is also possible that the locally produced HtrA1 by osteoclasts
and osteoblasts may contribute to the homeostasis of cartilage-
subchondral bone interface. In addition, given that HtrA1 is widely
expressed in many tissues; including brain, heart and ovary, it re-
mains to be determined whether HtrA1, as a secreted protein,
when is produced in excess by other cell types in disease condi-
tions might contribute to the bone and joint pathogenesis.
The role of other HtrA family proteins HtrA2, HtrA3 and HtrA4
in bone cells is hitherto unknown. Based on sequence analyses,
HtrA2 appears to be a mitochondrial like protein. HtrA3 and HtrA4
are not signiﬁcantly regulated during osteoclast and osteoblast dif-
ferentiation when compared to HtrA1. It was suggested that HtrA3
has overlapping biological activities to HtrA1, but can function in a
complementary fashion in certain types of tissues [25]. To date, the
involvement of HtrA3 in the bone physiology and disease remains
to be elucidated.
In summary, our studies and other work suggest a unique mode
of action of HtrA1, in which HtrA1 is produced by both osteoclasts
and osteoblasts and as an exogenous factor negatively regulates
osteoblast differentiation, indicative of both autocrine and para-
crine mechanisms. HtrA1 does so, at least in part by suppressing
BMP2-induced activation of Smad1/5/8, ERK1/2 and p38 and the
gene expression of ALP, Runx2, OCN and OPN. Overall, HtrA1
may involve in tilting the balancing act during osteoclast and
osteoblast-mediated bone remodeling, and thus may serve as a po-
tential therapeutic target for the treatment of bone disorders.
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